BioTuesdays

Leerink upgrades Cardiovascular Systems

Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday.

“Now with two solid quarters in a row of stable-to-improving growth and a new CEO in place, we believe the company has reached a fundamental inflection point after several quarters of underperformance in light of sales force disruptions and poor execution,” writes analyst Danielle Antalffy.

“We have always believed that the company is well-positioned to be a market leader in a peripheral atherectomy market, growing sustainably in the high-single-digit range, and a coronary atherectomy market growing even faster, given its competitive advantage in both calcified lesions and below the knee – both heavily underpenetrated markets within the space,” she added.

Beyond the top line, she said the company’s recent efforts to control costs through a restructuring in March that includes an 8% reduction in the workforce could push the company to profitability faster than previously expected.

Ms. Antalffy said she now believes the company can become profitable by mid-to-late fiscal 2018, ending June 30, which is four quarters earlier than an earlier late fiscal 2019 assumption. And the company seems poised to turn cash flow positive even sooner – in the current fiscal year ending June 30, 2017.

“This pathway to profitability can and should enable Cardiovascular Systems to attract a broader investor base and attract new money to the name that can continue to support the shares,” she added.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.